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ABSTRACT 
Now a days the concept of controlled release is quiet popular amongst the formulation scientists. The aim of this 
study was to develop a once-daily sustained release matrix tablet of Nimesulide using hydroxyl propyl 
methylcellulose (HPMC K4M) as release controlling factor and to evaluate drug release parameters as per various 
release kinetic models. The tablets were prepared using wet granulation method. Total of five batches were prepared 
from which two selected batches were further evaluated. Different dissolution models were applied to drug release 
data in order to evaluate release mechanisms and kinetics. The “n” Value of both batches indicates that the drug 
release mechanism follows “Anomalous Transport”. From all these data it is quite clear that batch F2 is optimized as 
its release kinetic was found to be as per Korsmeyer Peppas model rather than first order of F4. 
KEY WORDS: Nimesulide; Carbopol 934 P; HPMC K4M; diffusion controlled. 
INTRODUCTION 
 
Since last two decades formulation scientists are more interested in controlled release formulation. This goal can be 
achieved either using polymer based matrix/reservoir system or by osmotic delivery. The prolonged release dosage 
forms have many advantages in safety and efficacy over immediate release products in that frequency of dosing can 
be reduced drug efficacy can be prolonged and the incidence of adverse effects can be decreased. Extended release 
drug formulations have been used since 1960’s from which drug is available over extended time period after oral 
administration. By incorporating the dose for 24 h into one tablet from which the drug is slowly released. This 
formulation helps to avoid the side effects associated with low concentration and high concentrations. The ideal drug 
delivery system should show a constant zero-order release rate and maintain the constant plasma concentrations.1 it 
can be utilized for chronomediated drug delivery. With minimum dose improvement in bioavailability is achieved 
with improvement in treatment efficacy.2 
Depending on the part of the release unit in which the drug diffusion takes place, diffusion controlled release 
systems are divided into matrix systems (also referred to as monolithic systems) and reservoir systems. In matrix 
systems diffusion occurs in pores located within the bulk of the release unit, and in reservoir systems diffusion takes 
place in a thin water-insoluble film or membrane, often about 5-20 ?m thick, which surrounds the release unit. 
Diffusion  through  the  membrane  can  occur  in  pores  filled  with  fluid  or  in  the  solid  phase  that  forms  the  
membrane.2,3 
Drug is release from a diffusion controlled release unit in two steps4,5 
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1. The Liquid that surrounds the dosage from penetrates the release unit and dissolves the drug. A 
concentration gradient of dissolved drug is thus established between the interior and the exterior of the 
release unit. 
2. The dissolved drug will diffuse in the pores of the release unit or the surrounding membrane and thus be 
released or alternatively, the dissolved drug will partition into the membrane surrounding the dose unit and 
diffuse in the membrane. 
A dissolution step is thus normally involved in the release process but the diffusion step is the rate-controlling step. 
The rate at which diffusion will occur depends on four variables: 1. the concentration gradients over the diffusion 
distance, 2. the area, 3. the distance over which diffusion occurs and 4. the diffusion co-efficient of the drug. Some 
of these variables are used to modulate the release rate in the formulation.2 
 




The following materials were used: Nimesulide (ACS chemicals, Mumbai) was utilized as active ingredient, HPMC 
K4M (Color con, Mumbai), Carbopol 934 P (Corel pharma chem), magnesium stearate and PVPK30 (Sd fine 
chemicals, Mumbai) were obtained and used as received. All other chemicals used were of analytical grade. 
 
2. Method of preparation 
 
Wet granulation method was utilized to prepare tablet.3  Accurately weighed  active ingredient (See Table 1) was 
sifted through sieve #20 and all other ingredients PVP K 30, HPMC K4M, Carbopol 934 P except magnesium 
stearate were sifted  through sieve #20 followed by the lubricant material Magnesium stearate 10.0 mg  was sifted 
through sieve#40. Then the active pharmaceutical ingredient and the intragranular (PVP K30) materials were loaded 
in a double cone blender and mixed for 15 min. Using a granulating agent(IPA) the dry mix was granulated and 
granulation was done till it forms uniform granules. The wet granular mass of the above step was taken in to a rapid 
air dryer. Then the wet mass was dried at an inlet temperature of 500oC and LOD of the dried granules should not be 
more than3%. Then the dried granules were sifted through sieve # 20. The sifted granules and the sifted extra 
granular  material  are  loaded  in  to  the  double  cone  blender.  They  were  mixed  for  5  min.  and  the  blend  was  
characterized for the different physical parameters. The prepared blend was compressed into tablets by using 16-
station rotary press, cadmach Ahmedabad-8,India.  
 
Table 1: Formulation ingredients of prepared batches 
Ingredients F1 F2 F3 F4 F5 
Nimesulide 500.0 mg 500.0 mg 500.0 mg 500.0 mg 500.0 mg 
PVP K 30 20.0 mg 20.0 mg 20.0 mg 20.0 mg 20.0 mg 
HPMC K4M 450.0 mg 300.0 mg 250.0 mg 200.0 mg 150.0 mg 
Carbopol 934 P 70.0 mg 120.0 mg 170.0 mg 220.0 mg 270.0 mg 
Magnesium stearate 10.0 mg 10.0 mg 10.0 mg 10.0 mg 10.0 mg 
Total weight 950 mg 950 mg 950 mg 950 mg 950  
 
 
3. Organoleptic properties6 
The prepared tablets were evaluated for organoleptic parameters like color, odour, taste and texture. 
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4. Angle of repose  
Angle of repose was determined by measuring the height, radius of the heap of the powder blend. A cut system 
funnel was fixed to a stand and bottom of the funnel was fixed at a height of 2 cm from the plane. Powder blend was 
placed in funnel and allowed to flow freely and measured the height and radius of the heap.7 
                                                  tan?=h/? 
Where, h = height of heap  
r = radius of heap    
 
 
Table 2: Angle of repose values 
Angle of repose (in degrees) Type of flow 
< 25 Excellent 
25-30 Good 
30-40 Satisfactory 
>40 Very poor 
 
5. Bulk density 
 
A bulk density is defined as the mass of powder divided by the volume. A bulk density is largely depends on the 
particle shape, as particles becomes more spherical in shape, bulk density is increase. In addition as granules size 
increase, bulk density decrease. Powder weighing 10 g was placed into 100 ml measuring cylinder. Volume 





6. Tapped density  
 
Tapped density is achieved by mechanically tapping a measuring cylinder containing a powder sample. After 
observing the initial volume, the cylinder is mechanically tapped and volume reading is taken until further volume 
changes are observed. The mechanical tapping is achieved by raising the cylinder and allowing it to drop under own 
weight a specific distance. Device that rotates the cylinder during tapping may be preferred to minimize any possible 
separation of the mass during tapping down.  
Cylinder dropping distance: 14 ± 2 mm at a normal rate of 300 drops / min. The final volume was recorded and the 
tap density was calculated by the following equation.                         
 
 




7. Compressibility index (Carr’s index) and hausner’s ratio 
Compressibility index of the drug was determined using the following formula   
 
It can be calculated as;  
8. Hardness test 
Hardness was measured using Monsanto hardness tester. For each batch ten tablets were tested. The force required 
to break the tablet is recorded. The hardness of tablets of each batch was measured in kg/cm2. 6 
9. Uniformity of weight 
The weight variation test was carried out by weighing 20 tablets individually, calculating the average weight, 
comparing the individual tablet weight to average weight. The tablet meet IP test if no tablet differs by more than 
two times of percentage deviation.8 
10. Friability Test 
Tablet friability is lower than conventional fast dissolving tablets prepared by low compression. The friability of a 
sample of 10 tablets was measured using a Roche Friabilator. Twenty pre-weighed tablets were rotated at 25 rpm for 
4 minutes /20-rotations. After 20 rotations, the friability (% weight lost) is typically less than 1%. 9 
11. Water absorption ratio/Swelling study 
 
A piece of tissue paper is placed in a small Petri dish and a tablet is put on the tissue paper allowing to completely 
wet. The wetted tablet is then weighted and water absorption ratio, R is determined using following equation; 
 
R = 100 × Wa –Wb/Wa 
 
Where, Wa = Weight of tablet after water absorption 
Wb = Weight of tablet before water absorption. 
 
12. Dissolution study and model fitting 
In-vitro release rate of prepared tablets will be carried out using United State Pharmacopoeia (USP) XXIV 
dissolution testing apparatus (Paddle type). Phosphate buffer pH 7.4 (900 ml) was utilized as dissolution medium. A 
sample of 10 ml of the solution is withdrawn from the dissolution apparatus. The sample volume is replaced with 
fresh dissolution medium. The samples are filtered through Whatman filter paper No 40 and analyzed in UV 
spectrophotometerat 403 nm. The percentage drug release is calculated using an equation obtained from the 
calibration curve. The data obtained are fitted in to different model so as to ascertain the release mechanism. 
RESULTS AND DISSCUSSSION 
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Experimental batches were validated to confirm the accuracy and reproducibility of physical and chemical 
characteristics. Tablets were compressed without any problem and do not require any change in ratio of excipient in 
formulation. Tablets prepared were smooth, shiny and do not require coating as for experimental purpose. With 
respect to organoleptic characterizations all batches are smooth, light yellow with slight bitter taste afterward. 
 
1. Granule and tablet characterization 
 
The prepared granules and tablets were evaluated so as to check its efficacy. The attributes that are ascertained are 
summarizes in Table 3. It can be seen from the table that all are within the phrmacopoeial limits which adjudicates 
its suitability as a dosage unit. 




F1 F2 F3 F4 F5 
Angle of 
repose(?) 
29.02±0.12 30.11±0.34 32.01±0.21 33.21±0.34 39.21 ± 0.72 
Tapped density 0.51±0.002 0.54 ±0.0005 0.57±0.001 0.53±0.001 0.52±0.001 
Bulk density 0.43±0.002 0.47±0.001 0.39±0.001 0.49 ±0.001 0.48±0.0005 
Carr’s index 15.68±1.08 12.96 ±1.10 31.58±1.02 7.5 ± 2 12.87±1.04 
Hausner’s ratio 1.18 ±0.02 1.13 ±0.01 1.46 ±0.01 1.08 ± 0.2 1.18±0.016 
Hardness  4.2 kg/cm2 ± 
0.15 
4.33 kg/cm2 ± 
0.35 
3.8 kg/cm2 ± 
0.46 
4.5 kg/cm2 ± 
0.57 
4.8 kg/cm2 ± 
0.74 
Friability 0.532 % 0.285 % 0.817 % 0.292 % 0.436 % 
% swelling (2 h) 52 % ± 2 60 % ± 1 62 % ± 4 67 % ± 2 72 % ± 2 
Uniformity of 
weight 
950 ± 2.3 950 ±1.48 950 ±1.08 950 ± 1.8 950 ± 1.67 
 
 
From the results given in table 3 total two batches (F2 and F4) were selected for further evaluation as they were 
found optimum with respect to desired criteria. Weight variation is being done using five tablets as shown in Table 
4.Five tablets are weighed individually and average weight taken. The weight of tablet deviate from average weight 
is calculated. 
Table 4: Weight variation test 
SR NO. 
WEIGHT VARIATION 
A B mg F2 F4 
1 210 mg 205 1.25% 1.68% 
2 215 mg 210 3.61% 4.16% 
3 200 mg 190 3.56% 5.75% 
4 212 mg 208 2.16% 3.71% 
5 200 mg 195 3.56% 3.27% 
  =1037/5 
=207.5 
=1008/5 
=201.6     
 
 





2. Dissolution study and model fitting 
 
For the controlled release under investigation, which is a matrix-tablet comprising drug, and hydrophilic polymer, 
the release should follow three steps. First step is the penetration of the dissolution medium in the tablet matrix 
(hydration). Second step is the swelling with concomitant or subsequent dissolution or erosion of the matrix and 
third step is the transport of the dissolved drug, either through the hydrated matrix or from the parts of the eroded 
tablet, to the surrounding dissolution medium. The comparative dissolution profiles of both batches are given in 
figure 1. Model fitting of obtained data is summarized in Table 5 and Figure 2. From all these data it is quite clear 
that  batch  F2 is  optimized as  its  release  kinetic  was  found to  be  as  per  Korsmeyer  Peppas  model  rather  than  first  




Figure 1: Comparative dissolution profile of selected batches (n = 3, ± SD) 
From the dissolution profile it is clearly seen that batch F2 is more reliable in terms of drug release and all other 
aspects hence it was found to be most cogent from the experimental point of view. Hence it is selected for model 
fitting.   
Table 5: Model fitting of batches 










R2 0.9255 0.9750 0.9791 0.9586 0.9619 
SSR 191.18 0.137 35.675 0.094 1.317 
Batch 
F4 
R2 0.9198 0.9633 0.9592 0.18 3.542 
SSR 168.151217 0.002893 178.31 0.9177 0.951 
 













Figure 2: Model fitting graph of optimized batch F2 




The study aimed to prepare extended release tablet of Nimesulide. Total five batches were prepared from which two 
are selected for further evaluation. The weight variation of tablet test was passed for the selected batches. The 
hardness  is  enough for  conventional  dosage  route.  % CPR is  above 50 % after  two days.  The  “n”  Value  of  both  
batches indicates that the drug release mechanism follows “Anomalous Transport”. Swelling property is good for 
sustained release. Friability study Test passes in both batches. In short the prepared batches especially F2 matches 
the desirability criteria. 
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